Amgen has shared (PDF) the first phase 3 data on its $400 million eczema drug, linking the | Amgen has shared the first phase ...
After more than a decade without any therapeutic advancements in chronic obstructive pulmonary disorder (COPD), people with ...
Dupixent is indicated for the approximately 300,000 adults in the U.S. with inadequately controlled chronic obstructive pulmonary disease (COPD) ...
Regeneron (REGN) and Sanofi's (SNY) asthma therapy Dupixent receives FDA approval for label expansion in treating certain ...
Approval follows EU approval of Dupixent for adults with COPD with raised blood eosinophils, and is based on two landmark Phase 3 trials showing ...
“Dupixent has a proven track record as a first-in-class medicine, providing benefit to the many patients suffering from type 2 inflammatory related diseases such as asthma and atopic dermatitis.
Dupixent has received regulatory approvals in more than 60 countries in one or more indications including certain patients with atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps ...
Amgen reports mixed results from Phase 3 trials, with rocatinlimab showing moderate success in atopic dermatitis and Uplizna ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback